Novartis Enters Agreement With Roche on Production of the Latter's Drug
April 15 2021 - 2:14AM
Dow Jones News
By Cecilia Butini
Swiss pharmaceutical major Novartis AG said Thursday that it has
entered into an initial agreement with healthcare company Roche
Holding AG for the production of the active pharmaceutical
ingredient for one of Roche's drugs.
Novartis said the agreement is to reserve capacity and implement
a technology transfer for the production of the active
pharmaceutical ingredient in Roche's Actemra/RoActemra, a
rheumatoid arthritis drug.
As part of the agreement, Roche's manufacturing expertise will
be transferred to Novartis's drug-substance site in Singapore
during the second quarter of the year, the company said.
The agreement follows similar deals that Novartis struck with
BioNTech SE and CureVac NV to provide manufacturing capacity for
Covid-19 vaccines.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 15, 2021 01:59 ET (05:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024